Tirzepatide Research# SURPASS program (Type 2 diabetes): Five Phase 3 trials demonstrating superior HbA1c reduction compared to insulin glargine, semaglutide, and insulin degludec SURMOUNT program (Obesity): Phase 3 trials showing up to 20.9% weight loss at 72 weeks FDA approvals : Mounjaro (May 2022) for T2D
Nat Commun 13(1):92 Laurindo LF, Barbalho SM, Guiguer EL et al (2022) GLP-1a: going beyond traditional use
Subcutaneous bioavailability is high, meaning most of the medication reaches your bloodstream and produces its intended effects
Medical support: Your doctor is familiar with these medications and can manage side effects and dose adjustments Quality assurance: FDA-approved drugs are manufactured under strict standards
Under general anesthesia or deep sedation, that same slowing becomes a different kind of problem
Second, dramatic liver fat clearance